Combination Therapy to block Cancer Metastasis and Progression

Case ID:
C13909
Disclosure Date:
12/4/2015
Description:
Unmet need:  Oncology and cancer therapeutics need new targets and new multimodal therapeutics to treat or prevent tumor metastasis and progression.
 
Technology Overview:  The technology identifies an upregulated level of two interleukins that can be used as a diagnostic and prognostic tools for metastatic disease and as a therapeutic target.  First, Interleukin 6 and Interleukin 8 have been identified to play important roles in tumor progression and metastasis. The synergistic mechanism between the two interleukins promotes cancer cell migration in metastatic cell lines through a pathway that includes Janus kinase 2 (JAK2), signal transducer and activator of transcription 3 (STAT3), Wiskott-Aldrich syndrome protein family member 3 (WASF3), and the Actin Related Proteins (ARP) 2/3 complex.  Second, this synergistic pathway can be inhibited by a combination of Tocilizumab and Reparixin which block the cognate receptors of IL6 and IL8. Therapy using Tocilizumab and Reparixin in combination inhibits the synergistic pathway more than the two agents alone, and this combination of drugs in a specific ratio can be used for therapeutic purposes against metastatic disease.
 
Patent Status:  Pending US application 2017-0165363 A1
 
Associated Publications: Press Release; Nat Commun. 2017 May 26;8:15584.
 
Patent Information:
Title App Type Country Serial No. Patent No. File Date Issued Date Expire Date Patent Status
CANCER CELL MIGRATION INHIBITORS AND THEIR USE IN THERAPEUTIC TREATMENTS ORD: Ordinary Utility United States 15/372,796 12/8/2016     Pending
Inventors:
Category(s):
For Information, Contact:
Vera Sampels
vsampel2@jhu.edu
410-614-0300
Save This Technology:
2017 © Johns Hopkins Technology Ventures. All Rights Reserved. Powered by Inteum